# A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

> **NCT00486759** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 787 (actual)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Rituximab
- **DRUG:** CHOP
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00486759
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07-26
- **Primary completion:** 2011-11-30
- **Final completion:** 2011-11-30
- **Target enrollment:** 787 (ACTUAL)
- **Why stopped:** Due to an unfavorable benefit/risk ratio.
- **Last updated:** 2017-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486759, "A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00486759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*